榴莲视频

A drug comeback, new FDA approvals, and a new standard for transplant-ineligible patients

Results of FELIX study supported obecabtagene autoleucel's recent FDA approval

Agency is evaluating the need for further regulatory action

News, features, and commentary about cancer-related issues

Complete responses in 21% of patients treated with single-agent revumenib

News, features, and commentary about cancer-related issues

Improvements seen in pain, neuropathy, and cognitive function

Health news and commentary gathered by 榴莲视频 staff

Obecabtagene autoleucel has no requirement for a REMS program

Momentum grows for earlier intervention, including pre-fibrotic disease

News, features, and commentary about cancer-related issues

Largest survival benefit observed in patients who entered a cessation program within 6 months

News, features, and commentary about cancer-related issues

May become "treatment of choice" over brentuximab vedotin for all disease stages